Clinical trial NCT02348788: Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia
Official title: Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Plasmodium Vivax Malaria Without Complication
Keywords: Vivax
Malaria
artemether-lumefantrine
chloroquine
RCT
Lead sponsor: Menzies School of Health Research
Sponsor class: OTHER
Collaborators: name: Ministry of Health, Malaysia
First posted: 2015-01-28
Enrollment: 98
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Both artemether-lumefantrine and chloroquine are currently used and recommended by Malaysian Ministry of Health as blood stage treatments for non-severe P. vivax and P. knowlesi malaria. Microscopic misdiagnosis between Plasmodium species remains a large issue in Sabah, Malaysia and elsewhere. In order to facilitate potential policy change to a unified ACT guideline for all malaria species in Sabah artemether-lumefantrine needs to be evaluated for P. vivax malaria.

Preliminary data in a recently completed RCT evaluating artesunate-mefloquine vs chloroquine for P. vivax showed up to 36% P. vivax recurrence with chloroquine monotherapy by day 28 post treatment without primaquine. Based on these data blood stage chloroquine treatment failure rates should also be evaluated in the context of standard concurrent (rather than delayed) liver stage primaquine dosing, due to both its potential blood stage synergistic effect in addition to known decreased recurrence rates. As artemether-lumefantrine is one of the current first line Ministry of Health ACTs used in Sabah with a lower adverse event profile compared to artesunate-mefloquine, this was recommended as the more appropriate ACT to evaluate against chloroquine.

Detailed description: Malaria due to infection with P. vivax is currently estimated at up to 390 million episodes per year worldwide, with substantial morbidity caused by the recurrent nature of its infection, associated anaemia and adverse effects on pregnancy, and ability to cause severe disease and death. The majority of malaria cases from all Plasmodium species in Malaysia are from the Eastern state of Sabah, where despite around a 36-fold reduction in incidence since the implementation of malaria eradication programs in 1961, minimum estimates based on unpublished microscopy data from Sabah State public health records still detailed 8685 malaria cases in 2009-2011. While P. vivax accounts for between 30-50% of these figures currently, studies have demonstrated as overall transmission rates in countries previously endemic for malaria decline the proportion of cases attributable to P. vivax increases. Mixed P. falciparum / P. vivax infections are also likely to be underestimated in areas of co-endemicity, with high rates of recurrence of P. vivax shown in studies following treatment for apparent P. falciparum mono-infection or mixed Plasmodium spp. infections.

Malaysian Ministry of Health guidelines currently recommends chloroquine and primaquine as first line treatment for the erythrocytic and hypnozoite life stages of uncomplicated P. vivax malaria respectively. While resistance to chloroquine has previously been documented in Sabah and also Peninsular Malaysia, the unstable transmission dynamics and recent reduction in P. vivax incidence due to public health measures mean the current risk of chloroquine-resistant P.vivax transmission is likely to be low. Despite this, due to documented increasing resistance in surrounding countries including Indonesia, Thailand, Vietnam, and PNG, transient populations of migrant workers, and recent concerns of the failing efficacy of hypnozoite eradication by primaquine, the need for ongoing therapeutic efficacy monitoring is recommended.

There is also growing support for artemisinin-based combination therapy (ACT) as a unified first line treatment choice in areas co-endemic for P. falciparum and P. vivax, as adopted by a small number of countries including PNG, Solomon Islands, Vanuatu and Papua, Indonesia, due to the regional increase of chloroquine-resistant P. vivax, and ongoing concerns over the microscopic misdiagnosis of Plasmodium species. This is also particularly relevant for P. knowlesi malaria, as it is frequently misidentified on microscopy as P. falciparum and P. malariae due to morphological similarities in the early trophozoite, and late trophozoite and schizont life stages respectively, with studies showing up to 80% of P. malariae and 7-12% of P. falciparum in this region are actually P. knowlesi when definitively evaluated with PCR. Misdiagnosis has concerning treatment implications, as although P. knowlesi has been shown to respond well to ACT and chloroquine, unlike P. malariae, knowlesi malaria has a rapid 24-hour replication rate and can cause hyperparasitaemia, severe complications and fatal outcomes, while the inadvertent use of chloroquine for widely chloroquine-resistant P. falciparum may also have fatal consequences.

Previous reluctance to use ACTs in presumed chloroquine-sensitive P.vivax areas were centered on concerns over efficacy and cost. The advent of generically produced ACTs is improving cost-related issues, while a recent Cochrane review of clinical trials looking at the use of ACT versus chloroquine for uncomplicated vivax malaria showed that ACTs are equivalent to chloroquine in preventing recurrent parasitaemia in the first 28 days (RR 1, 95% CI 0.30 to 3.39), and those with long half lives such as mefloquine or piperaquine are superior over a 6-8 week follow up, with fewer recurrent episodes after day 28 (RR 0.47, 95% CI 0.29 to 0.76). This post treatment prophylaxis benefit of longer acting agents extends to the reduction in gametocyte carriage, delay in relapse or re-infection and decreased risk of anaemia development, all of which contribute to decreased transmissibility and health care cost.

Eligibility criteria: Inclusion Criteria:

* Male and female patients at least 1 year of age and weighing more than 10kg
* Microscopic diagnosis of P. vivax monoinfection
* Negative P. falciparum malaria rapid diagnostic test (histidine-rich-protein 2)
* Fever (temperature ≥37.5°C) or history of fever in the last 48 hours
* Written informed consent to participate in trial

Exclusion Criteria:

* Clinical or laboratory criteria for severe malaria, including warning signs, according to modified WHO 2010 criteria
* Parasitaemia \> 100,000 /μL
* Pregnancy or lactation
* Known hypersensitivity or allergy to study drugs
* Serious underlying disease (cardiac, renal or hepatic)
* Received anti-malarials in previous 2 months
* History of psychiatric illness, epilepsy, or cerebral malaria

Primary outcomes:
measure: Parasite clearance at 48 hours
timeFrame: 48 hours
Secondary outcomes:
measure: Parasite clearance time in hours
timeFrame: Within 72 hours post treatment
measure: Parasite clearance at day 1 and day 3
timeFrame: At 24 and 72 hours post treatment
measure: Treatment outcome
timeFrame: Day 28 and 42 post treatment
measure: Risk of anaemia
timeFrame: Day 28 post treatment
measure: Fractional fall in haemoglobin at day 3
timeFrame: Day 3 post treatment
measure: Haemoglobin nadir
timeFrame: 42 days post treatment
measure: Risk of P. vivax gametocyte carriage during follow up
timeFrame: 42 days
measure: Risk of adverse events
timeFrame: 42 days
measure: Length of hospital inpatient stay
timeFrame: From 2-9 days post enrolment
Other outcomes:
Locations:
city: Kota Marudu
country: Malaysia
facility: Kota Marudu District Hospital
state: Sabah
city: Kudat
country: Malaysia
facility: Kudat District Hospital
state: Sabah
city: Pitas
country: Malaysia
facility: Pitas District Hospital
state: Sabah
Study officials:
affiliation: Ministry of Health, Malaysia
name: Timothy William, MBBS, FRCP
role: PRINCIPAL_INVESTIGATOR
References: